Medicines

Fulltext search

For help on how to get the results you want, see our search tips.

Search results

Categories

Human Remove Human filter Veterinary (25) Apply Veterinary filter

Medicine name

Active substance / international non-proprietary name (INN) / common name

Medicine

European public assessment reports (EPAR) Remove European public assessment reports (EPAR) filter Paediatric investigation plans Remove Paediatric investigation plans filter Referrals Remove Referrals filter Direct healthcare professional communication Remove Direct healthcare professional communication filter Summaries of opinion (18) Apply Summaries of opinion filter Withdrawn applications (80) Apply Withdrawn applications filter Orphan designations (257) Apply Orphan designations filter

Product number

Authorisation status

Authorised (456) Apply Authorised filter Refused (18) Apply Refused filter Withdrawn (74) Apply Withdrawn filter

ATC code

Marketing authorisation date

From:

To:

Marketing authorisation holder

Pharmacotherapeutic group

Date of opinion

From:

To:

PIP decision type

P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s) (11) Apply P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s) filter PM: decision on the application for modification of an agreed PIP (74) Apply PM: decision on the application for modification of an agreed PIP filter W: decision granting a waiver in all age groups for all conditions or indications (11) Apply W: decision granting a waiver in all age groups for all conditions or indications filter

PIP condition / indication

Pharmaceutical form(s)

Route(s) of administration

Decision date

From:

To:

PIP compliance check

Yes (18) Apply Yes filter

Compliance procedure number

Referral name

Referral status

European Commission final decision (3) Apply European Commission final decision filter Opinion provided by Committee for Medicinal Products for Human Use (1) Apply Opinion provided by Committee for Medicinal Products for Human Use filter

Referral safety status

Yes (2) Apply Yes filter

Referral type

Article 31 referrals (3) Apply Article 31 referrals filter Article 20 procedures (1) Apply Article 20 procedures filter

Referral reference number

Referral decision making model

PRAC-CHMP-EC (3) Apply PRAC-CHMP-EC filter

Referral authorisation model

Centrally and nationally authorised products (mixed) (3) Apply Centrally and nationally authorised products (mixed) filter Centrally authorised product(s) (1) Apply Centrally authorised product(s) filter

Referral PRAC recommendation

Risk minimisation measures (1) Apply Risk minimisation measures filter Variation (1) Apply Variation filter

Referral procedure start date

From:

To:

Referral PRAC recommendation date

From:

To:

Medicine type

Biosimilar Remove Biosimilar filter Generic Remove Generic filter Orphan medicine Remove Orphan medicine filter Accelerated assessment (83) Apply Accelerated assessment filter Additional monitoring (633) Apply Additional monitoring filter Conditional approval (91) Apply Conditional approval filter Exceptional circumstances (63) Apply Exceptional circumstances filter

Related medicine

Therapeutic area

Last updated

From:

To:

This week This month Last week Last month

First published

From:

To:

665 results

Remove all filtersRemove all filters

Categories Human Remove Human filter

Medicine type Generic Remove Generic filter Biosimilar Remove Biosimilar filter Orphan medicine Remove Orphan medicine filter

Medicine Referrals Remove Referrals filter Paediatric investigation plans Remove Paediatric investigation plans filter Direct healthcare professional communication Remove Direct healthcare professional communication filter European public assessment reports (EPAR) Remove European public assessment reports (EPAR) filter

Sort by

List item

Human medicine European public assessment report (EPAR): Imnovid (previously Pomalidomide Celgene) (updated)

Pomalidomide, Multiple Myeloma
Date of authorisation: 05/08/2013, , , Revision: 22, Authorised, Last updated: 15/05/2023
List item

Human medicine European public assessment report (EPAR): Darunavir Krka (updated)

darunavir, HIV Infections
Date of authorisation: 26/01/2018, , Revision: 10, Authorised, Last updated: 15/05/2023
List item

Human medicine European public assessment report (EPAR): Bylvay (updated)

Odevixibat, Cholestasis, Intrahepatic
Date of authorisation: 16/07/2021, , , , Revision: 2, Authorised, Last updated: 12/05/2023
List item

Human medicine European public assessment report (EPAR): Tibsovo (updated)

Ivosidenib, Leukemia, Myeloid, Acute; Cholangiocarcinoma
Date of authorisation: 04/05/2023, , , Authorised, Last updated: 12/05/2023
List item

Human medicine European public assessment report (EPAR): Pemazyre (updated)

pemigatinib, Cholangiocarcinoma
Date of authorisation: 26/03/2021, , , , Revision: 5, Authorised, Last updated: 12/05/2023
List item

Human medicine European public assessment report (EPAR): Febuxostat Krka (updated)

febuxostat, Hyperuricemia; Gout
Date of authorisation: 28/03/2019, , Revision: 4, Authorised, Last updated: 11/05/2023
List item

Human medicine European public assessment report (EPAR): Rydapt (updated)

Midostaurin, Leukemia, Myeloid, Acute; Mastocytosis
Date of authorisation: 18/09/2017, , Revision: 10, Authorised, Last updated: 11/05/2023
List item

Human medicine European public assessment report (EPAR): Anagrelide Mylan (updated)

Anagrelide hydrochloride, Thrombocythemia, Essential
Date of authorisation: 15/02/2018, , Revision: 8, Authorised, Last updated: 11/05/2023
List item

Human medicine European public assessment report (EPAR): Kymriah (updated)

tisagenlecleucel, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Large B-Cell, Diffuse
Date of authorisation: 22/08/2018, , Revision: 14, Authorised, Last updated: 10/05/2023
List item

Human medicine European public assessment report (EPAR): Vegzelma (updated)

bevacizumab, Colorectal Neoplasms; Breast Neoplasms; Ovarian Neoplasms; Fallopian Tube Neoplasms; Peritoneal Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Uterine Cervical Neoplasms
Date of authorisation: 17/08/2022, , , Revision: 3, Authorised, Last updated: 10/05/2023
List item

Human medicine European public assessment report (EPAR): Deferasirox Accord (updated)

deferasirox, Iron Overload; beta-Thalassemia
Date of authorisation: 09/01/2020, , Revision: 4, Authorised, Last updated: 08/05/2023
List item

Human medicine European public assessment report (EPAR): Blincyto (updated)

blinatumomab, Precursor Cell Lymphoblastic Leukemia-Lymphoma
Date of authorisation: 23/11/2015, , , Revision: 17, Authorised, Last updated: 08/05/2023
List item

Human medicine European public assessment report (EPAR): Idelvion

albutrepenonacog alfa, Hemophilia B
Date of authorisation: 11/05/2016, , Revision: 11, Authorised, Last updated: 04/05/2023
List item

Human medicine European public assessment report (EPAR): Pioglitazone Teva

pioglitazone hydrochloride, Diabetes Mellitus, Type 2
Date of authorisation: 26/03/2012, , Revision: 12, Withdrawn, Last updated: 04/05/2023
List item

Human medicine European public assessment report (EPAR): Luxturna

voretigene neparvovec, Leber Congenital Amaurosis; Retinitis Pigmentosa
Date of authorisation: 22/11/2018, , , Revision: 6, Authorised, Last updated: 04/05/2023
List item

Human medicine European public assessment report (EPAR): Xenpozyme

Olipudase alfa, Acid sphingomyelinase deficiency (ASMD) type A/B or type B
Date of authorisation: 24/06/2022, , , Revision: 1, Authorised, Last updated: 03/05/2023
List item

Human medicine European public assessment report (EPAR): Tegsedi

inotersen sodium, Amyloidosis
Date of authorisation: 06/07/2018, , , Revision: 14, Authorised, Last updated: 02/05/2023
List item

Human medicine European public assessment report (EPAR): Ocaliva

Obeticholic acid, Liver Cirrhosis, Biliary
Date of authorisation: 12/12/2016, , , , Revision: 16, Authorised, Last updated: 02/05/2023
List item

Human medicine European public assessment report (EPAR): Fingolimod Mylan

fingolimod hydrochloride , Multiple Sclerosis, Relapsing-Remitting
Date of authorisation: 18/08/2021, , Revision: 4, Authorised, Last updated: 02/05/2023
List item

Human medicine European public assessment report (EPAR): Zejula

Niraparib (tosilate monohydrate), Fallopian Tube Neoplasms; Peritoneal Neoplasms; Ovarian Neoplasms
Date of authorisation: 16/11/2017, , , Revision: 20, Authorised, Last updated: 28/04/2023
List item

Human medicine European public assessment report (EPAR): Palynziq

Pegvaliase, Phenylketonurias
Date of authorisation: 03/05/2019, , , Revision: 7, Authorised, Last updated: 28/04/2023
List item

Human medicine European public assessment report (EPAR): Granupas (previously Para-aminosalicylic acid Lucane)

Para-aminosalicylic acid, Tuberculosis
Date of authorisation: 07/04/2014, , Revision: 11, Authorised, Last updated: 26/04/2023
List item

Human medicine European public assessment report (EPAR): Cinacalcet Mylan

cinacalcet hydrochloride, Hyperparathyroidism, Secondary; Hypercalcemia
Date of authorisation: 19/11/2015, , Revision: 15, Authorised, Last updated: 26/04/2023
List item

Human medicine European public assessment report (EPAR): Ambrisentan Mylan

ambrisentan, Hypertension, Pulmonary
Date of authorisation: 20/06/2019, , Revision: 4, Authorised, Last updated: 26/04/2023
List item

Human medicine European public assessment report (EPAR): Ravicti

glycerol phenylbutyrate, Urea Cycle Disorders, Inborn
Date of authorisation: 26/11/2015, , Revision: 16, Authorised, Last updated: 26/04/2023

Load more

665 results

Human medicine European public assessment report (EPAR): Imnovid (previously Pomalidomide Celgene) (updated)

Human medicine European public assessment report (EPAR): Darunavir Krka (updated)

Human medicine European public assessment report (EPAR): Bylvay (updated)

Human medicine European public assessment report (EPAR): Tibsovo (updated)

Human medicine European public assessment report (EPAR): Pemazyre (updated)

Human medicine European public assessment report (EPAR): Febuxostat Krka (updated)

Human medicine European public assessment report (EPAR): Rydapt (updated)

Human medicine European public assessment report (EPAR): Anagrelide Mylan (updated)

Human medicine European public assessment report (EPAR): Kymriah (updated)

Human medicine European public assessment report (EPAR): Vegzelma (updated)

Human medicine European public assessment report (EPAR): Deferasirox Accord (updated)

Human medicine European public assessment report (EPAR): Blincyto (updated)

Human medicine European public assessment report (EPAR): Idelvion

Human medicine European public assessment report (EPAR): Pioglitazone Teva

Human medicine European public assessment report (EPAR): Luxturna

Human medicine European public assessment report (EPAR): Xenpozyme

Human medicine European public assessment report (EPAR): Tegsedi

Human medicine European public assessment report (EPAR): Ocaliva

Human medicine European public assessment report (EPAR): Fingolimod Mylan

Human medicine European public assessment report (EPAR): Zejula

Human medicine European public assessment report (EPAR): Palynziq

Human medicine European public assessment report (EPAR): Granupas (previously Para-aminosalicylic acid Lucane)

Human medicine European public assessment report (EPAR): Cinacalcet Mylan

Human medicine European public assessment report (EPAR): Ambrisentan Mylan

Human medicine European public assessment report (EPAR): Ravicti